Treatment of hepatocellular carcinoma (HCC), with radiolabeled Lipiodol
| Autor: | Jong T. Lee, Byung Soo Kim, Jung Ho Suh, Hyung S. Yoo, Chan H. Park, Dong I. Kim |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Carcinoma Hepatocellular Iodine Radioisotopes Hepatic Artery Preliminary report Internal medicine Ascites medicine Humans Effective treatment Radiology Nuclear Medicine and imaging business.industry Liver Neoplasms Internal radiation Half-life Iodized Oil General Medicine Middle Aged medicine.disease Injections Intra-Arterial Hepatocellular carcinoma Lipiodol Female medicine.symptom Nuclear medicine business medicine.drug |
| Zdroj: | Nuclear Medicine Communications. 8:1075-1087 |
| ISSN: | 0143-3636 |
| DOI: | 10.1097/00006231-198712000-00018 |
| Popis: | Summary Fatty acid esters such as Lipiodol or Ethiodol (Savage Laboratories, Melville, New York) are known to selectively localize in vascular hepatocellular carcinomas (HCC), following intra-arterial hepatic administration. Lipiodol was labeled with radioactive 131I and administered in 47 patients with HCC for both imaging and therapy. The short term preliminary results suggest radiolabeled Lipiodol is effective in eliminating ascites, shrinking the rumor by a high internal radiation dose, and in improving symptomatology of these tumors. In the future, 90Y, which is a stronger pure beta-emitter (maximum beta energy of 2.27 MeV, a half life of 64 h, and a maximum penetration or beta range of 11mm), than 131I will be used for more effective treatment of HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|